Catch up on coverage from the third day of the 2023 SDPA Annual Summer Dermatology Conference.
With bimekizumab, the conservative imputation method led to higher response rates, achieved endpoints, and blocked IL-17A and IL-17F.
A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.
Joslyn Kirby, MD, discusses the importance of awareness and recognition in hidradenitis suppurativa from a clinician and patient perspective.
Megan Noe, MD, MPH, MSCE, reviews best practices for treating patients with cutaneous blisters and managing chronic bullous disorders.
Ahmad Amin, MD, FAAD, reviews biologic selection in patients with psoriatic disease.
For a full list of conference coverage from the SDPA Annual Summer Dermatology Conference, visit our conference page.